Purpose: To study the feasibility of induction chemotherapy added to concomitant cisplatin-based chemoradiotherapy (CRT) in patients with locally advanced head and neck cancer (LAHNC).
Introduction
Most locally advanced head and neck cancer (LAHNC) patients are treated with concomitant chemoradiotherapy, since it has been shown that 5-years survival increased with 6e8% as compared to radiotherapy alone [1] . The most common used schedule is the RTOG schedule with cisplatin 100 mg/m 2 on days 1, 22 and 43 combined with conventional radiotherapy [2] .Alternatively cisplatin 40 mg/m 2 combined with conventional or accelerated radiotherapy is applied [3e5] . A direct comparison of these two schedules with respect to toxicity, feasibility, or efficacy has not been performed yet.
Induction chemotherapy (IC) may improve the prognosis of LAHNC. Docetaxel, cisplatin and fluorouracil (TPF) has been proven superior to cisplatin and fluorouracil (PF) as induction chemotherapy in LAHNC with regard to efficacy and toxicity in two phase III studies, followed by radiotherapy alone, or by radiotherapy and concurrent carboplatin [6, 7] . The main criticism on these phase III studies is their omission to use standard concomitant cisplatin-based chemoradiotherapy after TPF. Before the start of our study, no data were available on the feasibility of cisplatincontaining TPF followed by cisplatin-based concomitant chemoradiotherapy. We conducted a randomized phase II study in which all LAHNC patients received TPF followed by randomization to either concomitant chemoradiotherapy with cisplatin 100 mg/m 2 once every 3 weeks with conventional radiotherapy (cis100 þ RT) or chemoradiotherapy with weekly cisplatin 40 mg/m 2 and accelerated radiotherapy (cis40 þ ART). The aim of this CONDOR study was to evaluate the feasibility of these schedules.
Patients and methods

Patients eligibility
Patients with pathologically proven non-metastatic, previously untreated, locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, stage III or IV, were eligible. Patients were between 18 and 65 years of age, had a WHO performance status of 0e1, adequate bone marrow, hepatic and renal function. Exclusion criteria were active alcohol addiction, admission for chronic obstructive pulmonary disease during the last 12 months, weight loss of more than 10% during the last 3 months prior to study entry.
The ethics committee of the participating centers approved the protocol and the study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Treatment
The TPF regimen was the same regimen as used in the EORTC 24971/TAX 323 study [7] . TPF was administered via a central venous catheter on an inpatient basis for the first two days. Thereafter the patients received the last 3 days of 5-FU using a medication cassette reservoir at home. After two cycles, radiological evaluation according to RECIST version 1.0 was performed. In case of complete response (CR), partial response (PR) or SD with minor response, patients were randomized and received another two cycles of TPF. Otherwise they were randomized and started concomitant CRT.
All patients started concomitant chemoradiotherapy between 3 and 6 weeks after the last cycle of TPF. Intensity-modulated radiation therapy (IMRT) technique was mandatory. Dose to gross tumor volume was 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions. Patients randomized to cis100 þ RT received cisplatin 100 mg/m 2 on days 1, 22 and 43 combined with conventional radiotherapy 5 fractions per week with a total treatment time of 7 weeks. Patients randomized to cis40 þ ART received weekly cisplatin 40 mg/m 2 for 6 cycles and accelerated radiotherapy of 6 fractions per week, with a total treatment time of 6 weeks. On one day of each week two fractions were delivered with an interval of at least 6 h.
Carboplatin AUC 1.5 weekly was given instead of cisplatin in case of MDRD <60 ml/min or ototoxicity grade 3 or 4. In case of neutrophils <1.5 Â 10 9 /l or platelets <100 Â 10 9 cisplatin was interrupted for one week or skipped in case of weekly cisplatin. Neck dissection was considered for patients with residual tumor.
Assessments
Adverse events were scored according to the NCIC-CTG Common Toxicity Criteria version 3.0. Late radiation toxicity in the follow-up was scored according to RTOG/EORTC criteria. Weight was assessed before the start of each cycle. In case of more than 10% weight loss or aspiration a feeding tube was placed.
Tumor evaluation was performed after 2 cycles of TPF, at the end of induction chemotherapy and 12 weeks after the end of chemoradiotherapy.
HPV status was determined with p16 immunohistochemistry and PCR [8] .
Quality of life questionnaires (EORTC QLQ-C30 and EORTC H&N53) were assessed and audiometry was performed at different time points (will be published separately).
Interim analysis by a data safety monitoring board (DSMB) was planned after treatment of 30 patients. Except for the primary endpoint, no stopping rules were defined.
Statistical analysis
Primary endpoint was feasibility of the treatment schedules. All patients were classified according to whether or not they completed the treatment based on receiving at least 90% of the scheduled total radiation dose. The secondary end points were toxicity, tumor response, progression free survival (PFS), overall survival (OS) and quality of life.
Based on a previous study in which 80% of the patients received 100% of the total radiation dose, we expected that 90% of the patients in our trial would receive at least 90% of the radiation dose. If 32 of the 35 patients in each arm completed treatment, we could conclude with 95% certainty that treatment was feasible in at least 80% of the patients. Therefore, a total of 70 patients were needed.
Time to progression was calculated from the date of treatment start to the date of the first tumor progression. Overall survival was determined by measuring the time from the start of treatment to the date of death. Cumulative survival data were calculated using the KaplaneMeier method. Feasibility was assessed by intention-to treat as defined as the population of all randomized patients analyzed in the arm they were assigned by randomization.
Results
Patients and treatment
Between December 2008 and February 2012 65 patients from three centers in the Netherlands were included. Of the 65 registered patients, 62 were assessable; two patients were excluded due to ineligibility and one patient withdrew consent ( Fig. 1) . Baseline demographic and clinical characteristics are shown in Table 1 . HPV status was positive in 13 patients, negative in 15 and unknown in 11 oropharyngeal cancer patients.
Sixty-two patients started with induction chemotherapy, 47 patients (75.8%) received four cycles of TPF. Four patients (6.5%) received only 3 cycles because of toxicity. Eight patients (12.9%) received only two cycles of TPF, of whom five patients because they did not show any response and three patients were treated off protocol due to rapid PD (n Z 2) and poor clinical condition due to toxicity (n Z 1). Three patients only received one TPF; one patient died after 1 TPF, one patient had an infective arthritis and was treated off protocol and one patient developed renal insufficiency.
Therefore, 56 patients were randomized to concomitant chemoradiotherapy, 27 patients to cis100 þ RT and 29 patients to cis40 þ RT. The mean RT dose in arm cis100 þ RT was 68.3 Gy (SD 1, 9) and in arm cis40 þ ART 69.0 Gy (SD 1.7). In arm cis100 þ RT, 6 (22.2%) and 17 (63.0%) patients received three and two cycles of cisplatin 100 mg/m 2 , respectively. Two patients completed protocol with carboplatin instead of cisplatin and two patients received one course cisplatin and two courses carboplatin. In arm cis40 þ ART 12 patients (41.4%) received all six planned cycles of cisplatin 40 mg/ m 2 , 8 (27.6%) patients received 5 cycles, 5 patients (18.5%) 4 cycles and 4 (13.8%) patients received only 3 cycles, of whom 2 patients also received one course carboplatin. The median dose cisplatin in both arms was 200 mg/m 2 .
The planned interim analysis after 30 randomized patients showed that 35% of the patients received the planned cisplatin dose during chemoradiotherapy in both arms. Therefore, the DSMB advised a second interim analysis after 50 randomized patients. This showed that only 32% of the patients received the planned cisplatin dose in the concomitant chemoradiation part of the study. Consequently, although almost all patients received at least 90% of the planned radiotherapy, the DSMB recommended stopping recruitment. At that moment 65 patients were registered instead of the planned 70 patients.
Toxicity
Chemotherapy and acute radiotherapy toxicities are listed in Table 2 . Grade 3 or 4 neutropenic fever occurred in 18% of patients during TPF, despite prophylaxis with GCS-F. There was one treatment related death after 1 TPF, probably due to a cardiac event in a patient with a medical history of hypertension. During TPF there were 31 hospitalizations in 25 patients.
Ninety-six percent of the patients in arm cis100 þ RT and 90% in arm cis40 þ ART experienced one or more grade 3 toxicities, whereas grade 4 toxicity occurred in 15% versus 14% of the patients. Mucositis grade 3/4 was seen in 26% versus 59% of the patients in arm cis100 þ RT and arm cis40 þ ART, respectively (p < 0.05). The onset of any grade mucositis was earlier in cis40 þ ART than in cis100 þ RT: during week 1e3 in 72% versus 40%, respectively (p Z <0.05). In arm cis40 þ ART 5 patients were hospitalized due to severe mucositis needing ketamine or sufentanil intravenously, versus nil in the cis100 þ RT arm. Renal toxicity occurred in 62% in patients with cisplatin 100 mg/m 2 versus 14% in patients treated with weekly cisplatin (p < 0.05). Main reasons for delay or discontinuation of cisplatin were in arm cis100 þ RT nephrotoxicity (n Z 7) and neutropenia (n Z 5) and in arm cis40 þ ART thrombocytopenia (n Z 7) and mucositis (n Z 3).
In arm cis100 þ RT 74% and in arm cis40 þ ART 90% of the patients needed a feeding tube, for median 10 versus 12 weeks, respectively (ns). During TPF most patients gained weight with a median of 2 kg (SD 5.42). During concomitant chemoradiotherapy patients lost weight, median 5 kg (SD 4.14) and median 6 kg (SD 3.37) in arm cis100 þ RT and in arm cis40 þ ART, respectively (ns). None of the patients needed parental feeding.
Efficacy
After TPF four patients reached CR (6.5%), 34 PR (54.8%), 14 SD with minor response (22.6%), 5 SD without any response (8.1%) and two PD (3.2%); two patients were not evaluable and 1 patient died after 1 TPF. The total response rate (CR þ PR) was 61.3%.
Twelve weeks after chemoradiotherapy, response rate was 81.5% in arm cis100 þ RT and 72.4%, in arm cis40 þ ART. Three patients in each arm were not evaluable for response.
Elective neck dissections were performed in two of the randomized patients, 1 in each arm. First relapses occurred with local or regional disease site or both in 11%, 0% and 8% of the patients in arm cis100 þ RT and in 10%, 10% and 10% in arm cis40 þ ART, respectively. Distant metastases at first relapse were found in 2 patients in arm cis100 þ RT and in 1 patient in arm cis40 þ ART.
After a median follow-up of 38 months, two years PFS and OS for all 62 included patients were 65% and 72% respectively. For the randomized patients in arm cis100 þ RT 2 years PFS and OS were 70% and 78% and in arm cis40 þ ART 72% and 79% as shown in Fig. 2  (ns) . Four patients developed a second primary tumor in the follow-up. In oropharyngeal cancer patients 2 years OS was 80% in HPV negative and 92% in HPV positive patients.
Discussion
Our study shows that induction chemotherapy with TPF followed by cisplatin-based chemoradiotherapy is not feasible, as only 22% of the patients treated with cis100 þ RT and 41% of the patients treated with cisplatin cis40 þ ART could receive the planned cisplatin dose during chemoradiotherapy. The planned radiotherapy could be given to 96% of the patients in each arm. TPF IC was feasible since 76% of the patients received all 4 planned cycles, whereas another 13% of the patients discontinued after two not because of toxicity.
Since there is no proven survival benefit of IC compared to concomitant chemoradiotherapy, the latter remains standard therapy in patients with LAHNC [1, 9, 10] . Consequently, no concessions should be made in the total dose of cisplatin during chemoradiotherapy as we know that a cumulative dose of 200 mg/m 2 is needed for optimal antitumor activity [11, 12] . In two phase III studies investigating concomitant chemoradiotherapy with cisplatin 100 mg/m 2 on days 1, 22, 43 70e85% of the patients received all planned cisplatin, whereas ! 200 mg/m 2 cisplatin could be administered in approximately 90% of the patients [2, 13] .
In arm cis100 þ RT of our study only 85% received 200 mg/m 2 cisplatin and 69% in arm cis40 þ ART. We conclude that cisplatin-based CRT after IC with 4 cycles of TPF is not feasible.
There have been more studies in which IC with TPF has been studied. The TREMPLIN study investigated TPF followed by CRT with cisplatin versus bioradiotherapy for larynx preservation [14] . In this study, 47% of patients received the planned three cycles of TPF with a dropout rate after TPF of 24%. Of the 58 patients starting chemoradiotherapy with cisplatin 100 mg/m 2 only 42% completed full treatment. In both this and our study only approximately 30e40% of the patients received all planned cisplatin during chemoradiotherapy. The dropout rate after TPF in the TREMPLIN study however, was high (24% vs 10% in our study). Despite their observations, the investigators still concluded that this treatment schedule was feasible.
Another study reported on a retrospective analysis of TPF followed by chemoradiotherapy with cisplatin 100 mg/m 2 [15] . In that trial, only two to three courses of less-intense TPF (only 4 days of 5-fluorouracil) were planned and only 87% of the 66 patients received 3 courses. Nine patients (14%) received no CRT after TPF. Of the 59 patients receiving CRT, only 5% received all planned 3 cycles of cisplatin and only 66% of the patients could receive !200 mg/m 2 cisplatin. Grade 3 skin toxicity or mucositis occurred in 73% and 85% of the patients and there was a high rate of unplanned hospital admissions. Nevertheless, the authors stated that this schedule was feasible. Likewise, high toxicity rates were found in our study. Main differences between the two treatment arms were a high rate of renal toxicity in patients receiving cisplatin 100 mg/m 2 with conventional radiotherapy and a high rate of mucositis in the patients who received weekly cisplatin 40 mg/m 2 with accelerated radiotherapy. The high rate of mucositis is probably caused by the accelerated radiotherapy, as described earlier [5, 16] .
In our study we chose to treat patients with four courses of TPF, according to the TAX 323 regimen, which seemed less toxic than the schedule used in the TAX 324 [6, 7] . After TPF we decided to use the standard RTOG schedule of conventional radiotherapy with cisplatin 100 mg/m 2 versus accelerated radiotherapy with weekly cisplatin 40 mg/m 2 . Accelerated radiotherapy was selected because of the better local regional control over conventional radiotherapy, albeit without any benefit in overall survival [17, 18] .
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compares favorably to 2 years survival rates of 37e67% in other studies with IC and conventional chemoradiotherapy in LAHNC [2, 6, 7, 10, 13] . In the PARA-DIGM and DeCIDE trials, developed to compare IC directly with chemoradiotherapy, overall survival at 3 years were 70e78% [9, 10] . The high survival rates, even in the control arms, of these recent studies compared to earlier trials, may be, partly, explained by HPV status. Patients with HPV positive oropharyngeal cancers have better survival rates compared to HPV negative tumors [19] . Although HPV status was not determined in the PARADIGM and DeCIDE study, more than half of the included patients presented with primary tumors in the oropharynx. We found HPV positivity in half of the patients with oropharyngeal carcinoma.
In conclusion, based on our data we do not recommend TPF induction chemotherapy followed by cisplatin-based chemoradiotherapy in routine clinical daily practice, for non-organpreservation. Still, in exceptional cases, for example in patients with N3 stages with collapse, or with cranial nerve involvement, or when rapid response is mandatory, and organpreservation, it can be considered to give one or two courses TPF induction, followed by concomitant chemoradiotherapy.
